-
Founded in:
2006-12-22 -
Country:
China -
Address:
No. 1739, Middle Section of Kunlunshan Avenue, Lanzhou New District, Lanzhou City, Gansu Province -
Tax NO.:
916200007948829218 -
Registered Funds:
84.5 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Indometacin |
This product has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus.
More
This product has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus. |
53-86-1 | 23 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Gamma oryzanol |
This product has the function of regulating autonomic nervous system dysfunction and endocrine balance disorders.
More
This product has the function of regulating autonomic nervous system dysfunction and endocrine balance disorders. |
11042-64-1 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Aluminum hydroxide |
Anti-acid, mucosal protection, local hemostasis, etc., the effect is slow and long-lasting, but the efficacy is weak
More
Anti-acid, mucosal protection, local hemostasis, etc., the effect is slow and long-lasting, but the efficacy is weak |
0.135g | 21645-51-2 | 14 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Aluminum hydroxide |
Anti-acid, mucosal protection, local hemostasis
More
Anti-acid, mucosal protection, local hemostasis |
0.245g | 21645-51-2 | 14 |
| Magnesium trisilicate |
Anti-acid, mucosal protection, local hemostasis
More
Anti-acid, mucosal protection, local hemostasis |
0.105g | 14987-04-3 | 11 |
| Extract Belladonna soft liquid and powder |
Anti-acid, mucosal protection, local hemostasis
More
Anti-acid, mucosal protection, local hemostasis |
0.0026ml | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Carbamazepine |
Anticonvulsant, anti-epileptic, anti-neuropathic pain, anti-manic-depressive, improve symptoms of certain mental illnesses, anti-central diabetes insipidus. The mechanism may include: 1. Use-dependent blocking of various excitable cell membrane Na channels, inhibiting the occurrence and spread of abnormal high-frequency discharges; 2. Inhibition of T-type calcium channels; 3. Enhancement of the activity of central noradrenergic nerves; 4. Promoting the secretion of antidiuretic hormone (ADH) or increasing the sensitivity of effectors to ADH.
More
Anticonvulsant, anti-epileptic, anti-neuropathic pain, anti-manic-depressive, improve symptoms of certain mental illnesses, anti-central diabetes insipidus. The mechanism may include: 1. Use-dependent blocking of various excitable cell membrane Na channels, inhibiting the occurrence and spread of abnormal high-frequency discharges; 2. Inhibition of T-type calcium channels; 3. Enhancement of the activity of central noradrenergic nerves; 4. Promoting the secretion of antidiuretic hormone (ADH) or increasing the sensitivity of effectors to ADH. |
298-46-4 | 42 |